These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 851480)

  • 1. cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
    Ghanta VK; Jones MT; Woodard DA; Durant JR; Hiramoto RN
    Cancer Res; 1977 Mar; 37(3):771-4. PubMed ID: 851480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of MOPC 104E myeloma in plateau phase.
    Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
    Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A murine plasmacytoma model for screening active drugs for human myeloma.
    Hiramoto RN; Ghanta VK; Durant JR; Hiramoto NS
    Cancer Clin Trials; 1980; 3(4):395-402. PubMed ID: 7428144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
    Broun GO; Petruska PJ; Hiramoto RN; Cohen HJ
    Cancer Treat Rep; 1982 Feb; 66(2):237-42. PubMed ID: 7034931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor action of cis-dichlorodiammineplatinum(II) and the effectiveness of a combination with sarcolysine].
    Presnov MA; Konovalova AL; Romanova LF; Sof'ina ZP; Stetsenko AI
    Vopr Onkol; 1978; 24(4):53-60. PubMed ID: 654174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Modification of the toxic effects of cis-dichlorodiammineplatinum].
    Kulik GI; Chekhun VF; Pel'kis FP; Korol' VI; Boĭm TM
    Eksp Onkol; 1985; 7(6):55-8. PubMed ID: 4085400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor proliferation and chemotherapy in immunosuppressed mice.
    Ghanta VK; Shrestha K; Durant JR; Hiramoto RN
    Cancer Res; 1983 Mar; 43(3):1097-100. PubMed ID: 6825081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of transplantable mouse tumors with cis-dichlorodiammineplatinum(II) alone and in combination with sarcolysin.
    Presnov MA; Konovalova AL; Romanova LF; Sofina ZP; Stetsenko AI
    Cancer Treat Rep; 1978 May; 62(5):705-12. PubMed ID: 657156
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
    Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
    Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
    Corbett TH; Griswold DP; Wolpert MK; Venditti JM; Schabel FM
    Cancer Treat Rep; 1979 May; 63(5):799-801. PubMed ID: 455319
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
    Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
    Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Xenograft of human bronchial squamous cell carcinoma and its sensitivity to therapy].
    Bak M; Sugár J
    Orv Hetil; 1984 Dec; 125(52):3161-4, 3167. PubMed ID: 6549406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.